Search hospitals > Tennessee > Nashville

Tennessee Oncology PLLC

Claim this profile
Nashville, Tennessee 37203
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Solid Tumors
296 reported clinical trials
11 medical researchers
Photo of Tennessee Oncology PLLC in NashvillePhoto of Tennessee Oncology PLLC in Nashville

Summary

Tennessee Oncology PLLC is a medical facility located in Nashville, Tennessee. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Solid Tumors and other specialties. Tennessee Oncology PLLC is involved with conducting 296 clinical trials across 178 conditions. There are 11 research doctors associated with this hospital, such as Melissa Johnson, MD, Erika P Hamilton, Meredith A McKean, and David R. Spigel, MD.

Area of expertise

1Cancer
Global Leader
Tennessee Oncology PLLC has run 72 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 negative
2Breast Cancer
Global Leader
Tennessee Oncology PLLC has run 69 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
Stage III

Top PIs

Clinical Trials running at Tennessee Oncology PLLC

Breast Cancer
Cancer
Solid Tumors
Lymphoma
Lung Cancer
Non-Small Cell Lung Cancer
Follicular Lymphoma
Non-Hodgkin's Lymphoma
Ovarian Cancer
Bladder Cancer
Image of trial facility.

Sacituzumab Govitecan

for Triple-Negative Breast Cancer

This trial is testing a drug called sacituzumab govitecan-hziy, which targets and kills cancer cells. It focuses on patients with advanced triple-negative breast cancer who have limited treatment options. The drug works by attaching to cancer cells and releasing a substance that kills them. Sacituzumab govitecan-hziy is an FDA-approved treatment for metastatic triple-negative breast cancer, especially for patients who have already tried other treatments.
Recruiting4 awards Phase 3
Image of trial facility.

Elacestrant

for Breast Cancer

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Recruiting2 awards Phase 33 criteria
Image of trial facility.

BT5528

for Solid Cancers

This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to: * Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab * Learn more about the side effects of BT5528 * Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cancer (NSCLC), triple-negative breast cancer, head and neck cancer (HNSCC), and gastric/upper gastrointestinal cancer. * Learn more about BT5528 therapy alone and in combination with nivolumab.
Recruiting1 award Phase 1 & 214 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Tennessee Oncology PLLC?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security